Fundamental analysis 603368.SS (Guangxi LiuYao Group Co., Ltd)
Updated on 10/08/2026
Method and analysis by Lubin Danilo, founder of Lubin Investment. Score computed automatically, with no human opinion.
We analyzed Guangxi LiuYao Group stock against the 10 quality criteria of Lubin Investment. The company gets a quality score of 5/10, meaning medium quality, and a P/FCF valuation multiple of 6.8×.
Guangxi LiuYao Group trades at a low free cash flow multiple but fails part of our quality criteria. Mind the trap: a low price is not a discount if the business is deteriorating. The low multiple may simply reflect a real problem.
Sector: Medical Distribution. Listing: SS. Current price: 15.22 CNY.
Lubin scoring methodology
Guangxi LiuYao Group Co., Ltd (603368.SS)'s score is calculated automatically from 10 objective financial criteria, with no human intervention or opinion. Each criterion is validated (YES / PARTIAL / NO) based on thresholds drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran). The final score is the sum of validations.
The thresholds come from the financial literature, not from our preferences: see the valuation work of Aswath Damodaran (NYU Stern) and the SEC investor education resources (investor.gov).
The 10 quantitative criteria analyzed
- Profitable: net margin > 5%
- Growing revenue: revenue growing > 10%/year over 5 years
- Growing earnings per share: FCF per share adjusted for stock-based compensation, > 10%/year over 5 years
- Share count under control: stable or declining (net buybacks = value creation for shareholders)
- Growing revenue per employee: revenue and revenue per employee both grow ≥ 10%/year over 5 years; partial when only one growth driver reaches its tier (fallback: free cash flow margin > 10% when employee history is unavailable)
- Expanding margins: operating margin widens over 5 years (operating leverage)
- Return on invested capital: Cash ROCE > 15% per year
- Debt under control: net debt repayable in less than 3 years of free cash flow
- Earnings converted to cash: free cash flow exceeds accounting net income
- Net collection period: short or negative cash conversion cycle
Its price against peers
Against the 5 other Medical Distribution stocks we have scored, Guangxi LiuYao Group trades at 6.8× its free cash flow, versus a median of 18.1× for that basket. On price alone, Guangxi LiuYao Group is therefore cheaper than its peers. That says nothing about its quality: at Lubin Investment, quality and price are judged separately, and a low multiple is only a bargain if the quality holds up.
Frequently asked questions
Is Guangxi LiuYao Group a quality stock?
Guangxi LiuYao Group gets a quality score of 5/10 (medium quality), calculated over the 10 Lubin Investment criteria: profitability, revenue and free cash flow growth, share buybacks, margins, debt and return on capital.
How is Guangxi LiuYao Group's score calculated?
The score is the total of validated criteria (YES / PARTIAL / NO) using thresholds drawn from the financial literature (Warren Buffett, Mauboussin, Aswath Damodaran), automatically and with no human opinion.
What is Guangxi LiuYao Group's P/FCF?
The price-to-free-cash-flow (P/FCF) multiple of Guangxi LiuYao Group stock is 6.8×. At Lubin Investment, valuation is judged separately from quality.
Where to see Guangxi LiuYao Group's full analysis?
The full interactive analysis (10-criteria detail, history, P/FCF valuation, sector comparisons) is available at https://lubin-investment.com/analyse/603368.SS?lng=en.
Other stocks in the Medical Distribution sector
- PT Soho Global Health Tbk (SOHO.JK), score 10/10, P/FCF 28.3×
- McKesson (MCK), score 9/10, P/FCF 17.9×
- M1 Kliniken (M12.DE), score 9/10, P/FCF 9.8×
- PT Itama Ranoraya Tbk (IRRA.JK), score 8/10
Go further
👉 See the full interactive analysis of 603368.SS
Other resources : All stocks in the Medical Distribution sector.